Lindsey Roeker, MD
Harrup R et al. 5-year update of the MURANO trial in relapsed or refractory chronic lymphocytic leukemia following fixed-duration venetoclax-rituximab therapy. Pan Pacific Lymphoma Conference 2021.
Jacobs R et al. Efficacy and safety of ublituximab in combination with umbralisib (U2) in patients with chronic lymphocytic leukemia (CLL) by treatment status: A sub-analysis of the Phase 3 Unity-CLL study. ASH 2021;Abstract 3726.
Jurczak W et al. Three-year follow-up of the Ascend trial: Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia. ASH 2021;Abstract 393.
Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901. Abstract
Mato AR et al. Pirtobrutinib, a highly selective, non-covalent BTK Inhibitor in previously treated CLL/SLL: Updated results from the Phase 1/2 BRUIN study. ASH 2021;Abstract 391.
Niemann CU et al. Time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have undetectable MRD – Primary analysis from the randomized Phase II Vision HO141 trial. ASH 2021;Abstract 69.
Roeker LE et al. COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies. Blood 2021;138(18):1768-73. Abstract
Rogers KA et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2021;106(9):2364-73. Abstract
Siddiqi T et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2021;[Online ahead of print]. Abstract
Wierda WG et al. TRANSCEND-CLL-004 phase 1 cohort of lisocabtagene maraleucel (liso-cel) combined with ibrutinib for patients with relapsed/refractory CLL/SLL. iwCLL 2021;Abstract 1084088.
Wierda WG et al. Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations. Leukemia 2021;35(11):3059-72. Abstract
Jeff Sharman, MD
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated CLL: 4-year follow-up analysis of the randomized CLL14 study. EHA 2021;Abstract S146.
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated CLL: Results of the first randomized Phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Davids MS et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for CLL: A single-arm, open-label, phase 2 study. Lancet Oncol 2021;22(10):1391-402. Abstract
Eichhorst B et al. A randomized Phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international Intergroup GAIA (CLL13) trial. ASH 2021;Abstract 71.
Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900.
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Kater A et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab for first-line CLL: Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: The GLOW study. ASH 2021;Abstract 70.
Seymour JF et al. Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 3721.
Sharma S et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). ASH 2021;Abstract 4365.
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. ASCO 2021;Abstract 7509.
Tam C et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Tedeschi A et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from Arm D of the SEQUOIA (BGB-3111-304) trial. ASH 2021;Abstract 67.
Woyach JA et al. Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. ASH 2021;Abstract 639.